<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03542825</url>
  </required_header>
  <id_info>
    <org_study_id>OBGYN 003</org_study_id>
    <nct_id>NCT03542825</nct_id>
  </id_info>
  <brief_title>Oral Lactoferrin Versus Iron Supplementation During Pregnancy</brief_title>
  <official_title>Outcome of Oral Lactoferrin in Comparison to Amino Acid Chelated Iron and Ferrous Sulphate Supplementation During Pregnancy: A Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South Valley University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>South Valley University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Iron deficiency anemia (IDA) is the condition in which there is anemia due to a lack of iron.
      The oral route is preferred to the parenteral route to replace iron stores [Sharma JB; et
      al., 2004]. Inorganic iron has poor bio-availability in addition to many side effects,
      including gastrointestinal discomfort, nausea, vomiting, diarrhea and constipation and it may
      sometimes increase susceptibility to infection [ So¨lvell L; et al., 1970].
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Iron deficiency anemia (IDA) is the condition in which there is anemia due to a lack of iron.
      The oral route is preferred to the parenteral route to replace iron stores. This allows the
      normal mechanism of absorption to be used, in addition to being an inexpensive and effective
      treatment [Sharma JB; et al., 2004]. Inorganic iron has poor bio-availability in addition to
      many side effects, including gastrointestinal discomfort, nausea, vomiting, diarrhea and
      constipation and it may sometimes increase susceptibility to infection [ So¨lvell L; et al.,
      1970].

      Furthermore, routine iron supplementation has recently been challenged. The British Society
      for Hematology, Obstetric Hematology Group (BSH OHG) and the British Committee for Standards
      in Hematology (BCSH) recommend screening by Full blood count (FBC) at booking and at 28 weeks
      instead of universal iron supplementation [Pavord S. 2012]. Lactoferrin is a high-affinity
      cationic iron binding glycoprotein [Baker EN, 2005]. Bovine Lactoferrin is currently
      available pharmaceutical preparation. It is in to safe and effective in treating pregnant
      women suffering from ID and IDA [Mohamed Rezk, et al. 2015]. This study will compare the
      efficacy of these three available options.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">October 1, 2018</completion_date>
  <primary_completion_date type="Actual">September 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>3 groups of pregnant women will be assigned for each intervention</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Double blinded (participant and care giver)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>change in haemoglobin level after 4 weeks of use.</measure>
    <time_frame>4 weeks</time_frame>
    <description>difference in haemoglobin levelbetween before and after supplementation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>side effect profile</measure>
    <time_frame>4 weeks</time_frame>
    <description>All women will be asked to keep a diary of five potential gastrointestinal side effects (Epigastric pain, nausea, vomiting, diarrhoea and constipation).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Iron-deficiency</condition>
  <arm_group>
    <arm_group_label>Iron Sulphate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ferrous sulphate 150 mg iron capsule once daily for 3 consecutive months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amino acid Chelated</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>amino acid chelated iron capsule 15mg for 3 consecutive months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactoferrin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lactoferrin 100 mg sachets once daily for 3 consecutive months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactoferrin</intervention_name>
    <description>parallel use of the three drugs to compare the efficacy of each arm in prevention of anemia</description>
    <arm_group_label>Lactoferrin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron Supplement</intervention_name>
    <description>Iron Sulphate 150 mg once daily</description>
    <arm_group_label>Iron Sulphate</arm_group_label>
    <other_name>Iron Sulphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chelates, Iron</intervention_name>
    <description>Amino acid chelated iron capsules contain 15 mg</description>
    <arm_group_label>Amino acid Chelated</arm_group_label>
    <other_name>Amino acid chelated iron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • Pregnant women (aged 20-40 yrs.) with single fetus, in the second trimester, with normal
        haemoglobin level (Hb level ≥10.5 gm /dl) will be enrolled.

        Exclusion Criteria:

          -  Women with anaemia (Hb level ≤10.5 gm. /dl) due to any causes, such as chronic blood
             loss, haemolytic anaemia and thalassemia (including thalassemia trait).

          -  History of peptic ulcer.

          -  Medical complications with pregnancy (such as cardiovascular, thyroid, pituitary,
             nutritional, renal, liver diseases, diabetes mellitus (DM) and hypertension (HTN).

          -  Fetal abnormalities such as microcephaly, intrauterine growth restriction (IUGR).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammad AM Ahmed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>South Valley University, Qena Faculty of Medicine, Obstetrics and Gynecology Department, Qena, Qena, Egypt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>South Valley University, Qena Faculty of Medicine, Obstetrics and Gynecology Department</name>
      <address>
        <city>Qinā</city>
        <state>Qena</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Sharma JB, Jain S, Mallika V, Singh T, Kumar A, Arora R, Murthy NS. A prospective, partially randomized study of pregnancy outcomes and hematologic responses to oral and intramuscular iron treatment in moderately anemic pregnant women. Am J Clin Nutr. 2004 Jan;79(1):116-22.</citation>
    <PMID>14684407</PMID>
  </reference>
  <reference>
    <citation>Pavord S, Myers B, Robinson S, Allard S, Strong J, Oppenheimer C; British Committee for Standards in Haematology. UK guidelines on the management of iron deficiency in pregnancy. Br J Haematol. 2012 Mar;156(5):588-600. Erratum in: Br J Haematol. 2012 Aug;158(4):559.</citation>
    <PMID>22512001</PMID>
  </reference>
  <reference>
    <citation>Baker EN, Baker HM. Molecular structure, binding properties and dynamics of lactoferrin. Cell Mol Life Sci. 2005 Nov;62(22):2531-9. Review.</citation>
    <PMID>16261257</PMID>
  </reference>
  <reference>
    <citation>Abu Hashim H, Foda O, Ghayaty E. Lactoferrin or ferrous salts for iron deficiency anemia in pregnancy: A meta-analysis of randomized trials. Eur J Obstet Gynecol Reprod Biol. 2017 Dec;219:45-52. doi: 10.1016/j.ejogrb.2017.10.003. Epub 2017 Oct 4. Review.</citation>
    <PMID>29059584</PMID>
  </reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>May 20, 2018</study_first_submitted>
  <study_first_submitted_qc>May 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2018</study_first_posted>
  <last_update_submitted>December 27, 2018</last_update_submitted>
  <last_update_submitted_qc>December 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>South Valley University</investigator_affiliation>
    <investigator_full_name>Mohammad Abdel-Rahman Mohammad Ahmed</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Iron</keyword>
  <keyword>Deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Lactoferrin</mesh_term>
    <mesh_term>Iron Chelating Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD will be shared in unanonomous manner with the predetermined group of researchers.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>throughout the period of research until end of the study</ipd_time_frame>
    <ipd_access_criteria>IPD will be shared with the predetermined group of researchers as accepted by the local ethical and research committee.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

